Skip to main content
Fig. 4 | Clinical Epigenetics

Fig. 4

From: CTCF loss mediates unique DNA hypermethylation landscapes in human cancers

Fig. 4

Prostate and breast tumors of the TCGA harboring CTCF copy number loss demonstrate hypermethylation events. Alterations exhibit a distinct DNA methylation profile. a Primary prostate tumors from TCGA (n = 333) segregated by CTCF CN status, boxplots of RNA-Seq for CTCF mRNA demonstrating significantly altered expression in diploid versus deletion cancers (P < 0.03). b Volcano plot of Illumina Methylation 450k Array data for CTCF CN loss tumors versus CTCF diploid tumors reveals increased primarily hypermethylation events, prostate tumors. Dots represent individual probes; Black, above cut point (Absolute value log2-FC loss/diploid B-values > 0.5, Adj P < 0.01). c PCa cell line LNCaP CTCF ChIP-Seq (GSE33213) identified putative CTCF binding sites. The black bar is percentage of differentially methylated probes, and gray bar is percentage of total probes from HM450 array were calculated with respect to proximity to CTCF binding sites. d Primary breast tumors from the TCGA (n = 816) segregated by CTCF CN status, boxplots of RNA-Seq for CTCF mRNA. e Volcano plot of 450k Array for BRCA tumors; black, above cut point (absolute value log2-FC loss/diploid B-values > 0.5, Adj P < 0.01). f BCa cell line MCF7 CTCF ChIP-Seq (GSE30263) identified putative CTCF binding sites for BRCA samples. The black bar is percentage of differentially methylated probes, and gray bar is percentage of total probes from HM450 array were calculated with respect to proximity to CTCF binding sites. g Overlap comparisons of differentially methylated (DM) CTCF binding sites in prostate and breast tumors demonstrate distinct methylation profiles at CTCF sites, related to Additional file 2: Table S2

Back to article page